AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4
slide-5

Metadoze-IPR 500 Tablet SR

Prescription Icon
Prescription Required

Marketer

Biocon

Salt Composition

Metformin (500mg)

Overview Metadoze-IPR 500 Tablet SR

Iprandola 500mg Extended-Release Tablets are prescribed for managing type 2 diabetes mellitus, effectively regulating blood glucose and mitigating associated complications. This medication also addresses Polycystic Ovary Syndrome (PCOS) in women. For optimal absorption and to minimize gastrointestinal upset, ingest these tablets with food, consistently at the same time daily. Discontinuation should only occur under medical supervision. Successful diabetes management requires a holistic approach; adherence to your physician's dietary and exercise plan is crucial alongside medication. Commonly reported side effects include diarrhea, nausea, vomiting, gas, fatigue, dyspepsia, abdominal discomfort, headaches, and anorexia. Concurrent use with other antidiabetic medications, alcohol, or missed meals raises the risk of hypoglycemia (low blood sugar). Regular blood glucose monitoring is essential. Prior to commencing treatment, disclose any pre-existing kidney, liver, or cardiac conditions to your doctor. Pregnant or lactating individuals require medical consultation before use. Baseline kidney function tests will be conducted before prescription. Limit alcohol consumption to reduce the likelihood of adverse effects.

Uses of Metadoze-IPR 500 Tablet SR

Managing Type 2 diabetes and polycystic ovary syndrome (PCOS)

Major Benefits of Metadoze-IPR 500 Tablet SR:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. It is recommended to take Metadoze-IPR 500 SR Tablet with food.

Common Side effects of Metadoze-IPR 500 Tablet SR:

  • Diarrhea
  • Headache
  • Vomiting
  • Nausea
  • Flatulence
  • Abdominal discomfort
  • Weakness

How to use Metadoze-IPR 500 Tablet SR:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. The Metadoze-IPR 500 SR tablet should be taken with a meal.

How Metadoze-IPR 500 Tablet SR works:

Metformin extended-release 500mg tablets belong to the biguanide class of antidiabetic drugs. Their mechanism involves reducing hepatic glucose output, slowing intestinal glucose uptake, and enhancing insulin sensitivity.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol concurrently with Metadoze-IPR 500 Tablet SR is inadvisable due to safety concerns.

PregnancyPregnancySAFE IF PRESCRIBED

The extended-release Metadoze-IPR 500mg tablet is typically deemed safe for use during gestation. Preclinical trials in animals revealed minimal or no negative impact on fetal development; nevertheless, data from human trials are scarce.

Breast feedingBreast feedingCAUTION

Extended-release Metadoze-IPR 500 mg tablets require careful consideration when breastfeeding. Mothers should discontinue breastfeeding throughout their treatment course and until the medication is fully cleared from their system.

DrivingDrivingCAUTION

Driving may be impaired if your blood glucose level is abnormally low or high. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Exercise caution when prescribing Metadoze-IPR 500 SR tablets to individuals with impaired renal function; dosage modification may be necessary. Consult a physician for guidance. Metadoze-IPR 500 SR tablets are contraindicated in patients exhibiting severe kidney disease.

LiverLiverUNSAFE

Extended-release Metadoze-IPR 500mg tablets are contraindicated for individuals with hepatic impairment and should be avoided. Physician consultation is recommended.

What if you forget to take Metadoze-IPR 500 Tablet SR :

Should you forget a Metadoze-IPR 500 Tablet SR dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Metadoze-IPR 500 Tablet SR

LabelValue
Type of Compound Guanidine-based medication
Potential for Dependence None.
Type of Treatment Medication for diabetes

FAQs on Metadoze-IPR 500 Tablet SR

Individuals with type 2 diabetes exhibit impaired responsiveness to their own insulin. Consequently, blood glucose levels rise. Metadoze-IPR 500 Tablet SR employs multiple mechanisms to lower elevated blood sugar. This medication reduces hepatic glucose production, diminishes intestinal glucose absorption post-prandially, and enhances insulin sensitivity in tissues. This combined action facilitates improved glucose uptake from the bloodstream and augments the body's natural insulin response.
Individuals using Metadoze-IPR 500 Tablet SR have reported weight reduction, particularly among those classified as overweight or obese. This weight loss effect may also be observed in overweight and obese patients predisposed to diabetes. Furthermore, it's been noted in insulin-resistant or insulin-sensitive patients. However, self-medicating with this drug for weight management is inadvisable; physician consultation is always necessary.
Metadoze-IPR 500 SR tablets are among the initial treatments for hyperglycemia. This medication manages blood glucose by enhancing insulin responsiveness, reducing hepatic glucose production, and diminishing intestinal sugar absorption. Differing from other oral hypoglycemics, solo administration of Metadoze-IPR 500 SR tablets infrequently leads to hypoglycemia due to its inhibition of excessive insulin release. Beyond glycemic control, this medication also aids in weight management.
Metadoze-IPR 500 SR tablets typically don't induce drowsiness and are generally well-received. Infrequently, though, Metadoze-IPR 500 SR tablets can lead to sleep disturbances or insomnia. Somnolence might indicate a severe adverse reaction known as lactic acidosis, especially prevalent in individuals with impaired kidney function. Consult your physician if fatigue or sleepiness develops during Metadoze-IPR 500 SR treatment.
Administer Metadoze-IPR 500 Tablet SR with or following a meal. The tablets should be swallowed whole with water; do not crush or chew them. For once-daily regimens, take the tablet in the morning with breakfast. For twice-daily prescriptions, take one tablet with breakfast and the other with dinner. If three doses are prescribed, take them with breakfast, lunch, and dinner. Consuming Metadoze-IPR 500 Tablet SR with food helps mitigate potential gastrointestinal issues, such as indigestion, nausea, vomiting, diarrhea, abdominal pain, and anorexia.
Individuals with type 2 diabetes either produce insufficient insulin or exhibit impaired responsiveness to endogenous insulin. This results in elevated blood glucose concentrations. Metadoze-IPR 500 Tablet SR counteracts hyperglycemia through multiple mechanisms. It reduces hepatic glucose production, diminishes intestinal glucose absorption postprandially, and enhances insulin sensitivity in peripheral tissues. These actions facilitate improved glucose uptake from the bloodstream and augment the body's natural insulin response.
Individuals using Metadoze-IPR 500 SR tablets have reported weight reduction, particularly those classified as overweight or obese. This weight decrease may also be observed in overweight or obese patients predisposed to diabetes. Furthermore, insulin-resistant or insulin-sensitive patients might experience similar effects. However, self-medicating with this drug for weight management is strongly discouraged; professional medical guidance is necessary before initiating treatment.
Metformin extended-release 500mg is a frequently initial prescribed medication for individuals with hyperglycemia. This agent manages blood glucose by enhancing the body's insulin sensitivity, reducing hepatic glucose production, and diminishing intestinal glucose absorption. In contrast to other oral hypoglycemic agents, monotherapy with Metformin extended-release 500mg infrequently results in hypoglycemia due to its mechanism of action which avoids excessive insulin secretion. Beyond its efficacy in glycemic control, it also aids in weight management.
Metadoze-IPR 500 SR tablets generally don't induce drowsiness and are typically well-received. Infrequently, though, Metadoze-IPR 500 SR tablets might lead to sleep disturbances or insomnia. Somnolence can be a symptom of a severe adverse reaction known as lactic acidosis, especially if renal function is impaired. Consult your physician if fatigue or sleepiness develops during Metadoze-IPR 500 SR treatment.
Administer Metadoze-IPR 500 Tablet SR with food or immediately following a meal. The tablets should be swallowed whole with water; avoid crushing or chewing. For once-daily prescriptions, morning ingestion with breakfast is recommended. Twice-daily regimens should involve one tablet in the morning and one in the evening, alongside meals. Three times daily, distribute the tablets with breakfast, lunch, and dinner. Consuming Metadoze-IPR 500 Tablet SR during meals mitigates potential gastrointestinal distress, including indigestion, nausea, vomiting, diarrhea, abdominal pain, and appetite suppression.
Individuals with type 2 diabetes either produce insufficient insulin or exhibit impaired responsiveness to their body's insulin production. This leads to elevated blood glucose levels. Metadoze-IPR 500 Tablet SR employs multiple mechanisms to lower these elevated blood sugar levels. The tablet reduces hepatic glucose production, diminishes intestinal glucose absorption post-prandially, and enhances insulin sensitivity in bodily tissues. This combined action facilitates improved glucose uptake from the bloodstream. Furthermore, it promotes a more effective physiological response to naturally produced insulin.
Individuals overweight or obese using Metadoze-IPR 500 SR tablets may experience weight reduction. This effect might also be observed in overweight or obese patients predisposed to diabetes. Furthermore, insulin-resistant or insulin-sensitive patients could likewise lose weight while taking this medication. However, self-prescribing Metadoze-IPR 500 SR for weight loss is inadvisable; physician consultation is essential.
Metformin extended-release 500mg is frequently an initial treatment for hyperglycemia. This medication manages blood glucose by enhancing insulin sensitivity, reducing hepatic glucose production, and decreasing intestinal glucose absorption. Unlike some other oral hypoglycemics, Metformin, when used monotherapy, infrequently results in hypoglycemia due to its mechanism of action which avoids excessive insulin release. Beyond glycemic control, it also assists in weight management.
Extended-release Metadoze-IPR 500mg tablets typically do not induce drowsiness and are generally well-received. Infrequently, though, they may lead to sleep disturbances or insomnia. Drowsiness can be a symptom of a severe adverse reaction known as lactic acidosis, especially in individuals with impaired kidney function. Consult your physician immediately if fatigue or sleepiness develops during Metadoze-IPR 500mg tablet use.
Administer Metadoze-IPR 500 Tablet SR with or following a meal. Avoid crushing or chewing the tablets; ingest them whole with water. For a once-daily prescription, consume it in the morning with breakfast. For twice-daily doses, take one tablet with breakfast and the second with dinner. For thrice-daily regimens, distribute doses among breakfast, lunch, and dinner. Ingesting Metadoze-IPR 500 Tablet SR with food mitigates potential gastrointestinal distress such as indigestion, nausea, vomiting, diarrhea, abdominal pain, and anorexia.
Metadoze-IPR 500 Tablet S...
19
MRP 22
13% off